Physician profile
Mark E Molitch
NPI 1255365490
$52,572.86
in general payments reported to CMS, 2019-2025
18 companies · $2,682 in 2025
The $2,682 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $2,385 · 2021: $6,140 · 2022: $2,480 · 2023: $9,292 · 2024: $17K · 2025: $2,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,455 · Travel and Lodging: $1,303 · Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,220.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,455.00 |
| Travel and Lodging | $1,303.31 |
| Food and Beverage | $615.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $9,139.87 | 2024-2025 | |
| Novo Nordisk INC | $8,365.45 | 2019-2023 | |
| Lexicon Pharmaceuticals, INC. | $7,394.71 | 2024 | |
| Merck Sharp & Dohme LLC | $5,983.77 | 2019-2020 | |
| Horizon Therapeutics Plc | $5,200.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $4,000.00 | 2019 | |
| Amryt Pharma Holdings Ltd | $3,521.53 | 2022-2023 | Mycapssa |
| Recordati_rare_diseases_inc. | $2,750.00 | 2021 | |
| Xeris Pharmaceuticals, INC. | $1,800.00 | 2021 | |
| Chiesi USA, INC. | $1,565.33 | 2025 | Mycapssa |
| Chiasma, INC. | $1,150.00 | 2021 | |
| Opko Pharmaceuticals, LLC | $1,000.00 | 2024 | Rayaldee |
| Gilead Sciences, INC. | $440.00 | 2021 | |
| Corcept Therapeutics | $243.54 | 2019-2025 | Korlym |
| Lilly USA, LLC | $18.66 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Molitch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.